TG Therapeutics Files 8-K on Operations and Financials
Ticker: TGTX · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1001316
Sentiment: neutral
Topics: operations, financials, filing
Related Tickers: TGTX
TL;DR
TG Therapeutics dropped an 8-K on Nov 3rd covering financials and operations. Check it out.
AI Summary
On November 3, 2025, TG Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also includes financial statements and exhibits. The company, previously known as Manhattan Pharmaceuticals Inc., Atlantic Technology Ventures Inc., and Atlantic Pharmaceuticals Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This 8-K filing provides investors with crucial updates on TG Therapeutics' operational performance and financial health, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for operational and financial updates, not indicating any immediate or significant new risks.
Key Players & Entities
- TG Therapeutics, Inc. (company) — Registrant
- November 3, 2025 (date) — Date of earliest event reported
- Manhattan Pharmaceuticals Inc (company) — Former company name
- Atlantic Technology Ventures Inc (company) — Former company name
- Atlantic Pharmaceuticals Inc (company) — Former company name
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Business Address City
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated November 3, 2025.
What is the primary business of TG Therapeutics, Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'PHARMACEUTICAL PREPARATIONS [2834]', indicating their business is in pharmaceutical preparations.
What are the previous names of TG Therapeutics, Inc. mentioned in the filing?
The filing lists former company names as Manhattan Pharmaceuticals Inc, Atlantic Technology Ventures Inc, and Atlantic Pharmaceuticals Inc.
Where is TG Therapeutics, Inc. incorporated and what is its primary business address?
TG Therapeutics, Inc. is incorporated in Delaware and its business address is 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY 10014.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-11-03 07:34:54
Filing Documents
- tgtx20250909_8k.htm (8-K) — 28KB
- ex_860184.htm (EX-99.1) — 167KB
- 0001437749-25-032658.txt ( ) — 346KB
- tgtx-20251103.xsd (EX-101.SCH) — 3KB
- tgtx-20251103_def.xml (EX-101.DEF) — 12KB
- tgtx-20251103_lab.xml (EX-101.LAB) — 15KB
- tgtx-20251103_pre.xml (EX-101.PRE) — 12KB
- tgtx20250909_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 3, 2025, the Company issued a press release announcing results of operations for the three and nine months ended September 30, 2025. A copy of such press release is being furnished as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by TG Therapeutics, Inc., dated November 3, 2025 . 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TG Therapeutics, Inc. (Registrant) Date: November 3, 2025 By: /s/ Sean A. Power Sean A. Power Chief Financial Officer